News articles about Insmed (NASDAQ:INSM) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Insmed earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.7366881225151 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Insmed, Inc. (NASDAQ:INSM) Sees Significantly Lower Trading Volume - First News 24 (firstnewspaper24.com)
- Growth Factors Market Size to Escalate at a Rapid Scale Through 2021 (medgadget.com)
- Insmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017 (finance.yahoo.com)
- Insmed Inc (INSM) Sees Schaff Trend Cycle Trending Up - Evergreen Caller (evergreencaller.com)
- -$0.63 EPS Expected for Insmed, Inc. (NASDAQ:INSM) This Quarter (americanbankingnews.com)
Shares of Insmed (NASDAQ INSM) opened at 16.36 on Friday. The stock’s 50 day moving average price is $16.88 and its 200 day moving average price is $16.46. Insmed has a 52 week low of $10.21 and a 52 week high of $19.35. The firm’s market capitalization is $1.02 billion.
Insmed (NASDAQ:INSM) last issued its earnings results on Wednesday, May 3rd. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, meeting the consensus estimate of ($0.60). On average, analysts predict that Insmed will post ($2.49) EPS for the current fiscal year.
Several brokerages recently issued reports on INSM. Zacks Investment Research upgraded Insmed from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a report on Wednesday, July 5th. BidaskClub upgraded Insmed from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Stifel Nicolaus reiterated a “buy” rating and issued a $23.00 price target on shares of Insmed in a report on Tuesday, April 18th. Citigroup Inc. reiterated a “neutral” rating and issued a $17.00 price target (up from $14.00) on shares of Insmed in a report on Sunday, June 11th. Finally, Robert W. Baird began coverage on Insmed in a report on Monday, July 10th. They issued an “outperform” rating and a $23.00 price target for the company. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $22.00.
In other Insmed news, General Counsel Christine A. Pellizzari bought 10,000 shares of the firm’s stock in a transaction dated Wednesday, May 31st. The shares were acquired at an average cost of $15.14 per share, for a total transaction of $151,400.00. Following the transaction, the general counsel now owns 27,300 shares in the company, valued at $413,322. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.03% of the stock is currently owned by insiders.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
